Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 May;61(5):1756–1763. doi: 10.1128/iai.61.5.1756-1763.1993

Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.

M A Mascelli 1, B Frederick 1, T Ely 1, D S Neblock 1, D J Shealy 1, K Y Pak 1, P E Daddona 1
PMCID: PMC280762  PMID: 8478065

Abstract

Clinical data suggest that the human immunoglobulin M antiendotoxin antibody HA-1A reduced mortality in patients diagnosed with gram-negative bacteremia and bacteremia with shock. Previous studies have demonstrated that HA-1A binds to the lipid A domain of lipopolysaccharide (LPS). The present study evaluated the ability of HA-1A to interact with LPs isolated from various strains of gram-negative bacteria by using liquid-phase rate nephelometry and solid-phase immunoblotting assays. HA-1A formed immune complexes in solution with LPSs isolated from both rough and smooth gram-negative organisms. Western blot (immunoblot) analysis of these LPS preparations revealed that HA-1A bound to LPS isolated from rough gram-negative organisms and to a rough LPS-like component present in smooth LPS. HA-1A also bound to LPS-protein complexes found in certain commercial rough LPS preparations. Preincubation of HA-1A with lipid A completely blocked subsequent binding of HA-1A to LPS in both liquid- and solid-phase assay formats, suggesting that the interaction of HA-1A with LPS is through the lipid A domain. Evidence that the binding of HA-1A to LPS was mediated through the antigen-combining (Fv) region of the antibody was provided by the finding that a murine anti-idiotypic antibody to HA-1A inhibited binding. These findings suggested that the broad antiendotoxin reactivity exhibited by HA-1A appeared to be due to the ability of HA-1A to bind to the conserved lipid A moiety of LPSs derived from both smooth- and rough-phenotype gram-negative bacterial strains.

Full text

PDF
1756

Images in this article

1760Image
on p.1760
1760Image
on p.1760
1760Image
on p.1760
1761Image
on p.1761

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bogard W. C., Jr, Dunn D. L., Abernethy K., Kilgarriff C., Kung P. C. Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity. Infect Immun. 1987 Apr;55(4):899–908. doi: 10.1128/iai.55.4.899-908.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braude A. I., Ziegler E. J., Douglas H., McCutchan J. A. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis. 1977 Aug;136 (Suppl):S167–S173. doi: 10.1093/infdis/136.supplement.s167. [DOI] [PubMed] [Google Scholar]
  3. Brogden K. A., Phillips M. The ultrastructural morphology of endotoxins and lipopolysaccharides. Electron Microsc Rev. 1988;1(2):261–278. doi: 10.1016/0892-0354(88)90004-4. [DOI] [PubMed] [Google Scholar]
  4. Coughlin R. T., Bogard W. C., Jr Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS). J Immunol. 1987 Jul 15;139(2):557–561. [PubMed] [Google Scholar]
  5. Duncan R. L., Jr, Hoffman J., Tesh V. L., Morrison D. C. Immunologic activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro. J Immunol. 1986 Apr 15;136(8):2924–2929. [PubMed] [Google Scholar]
  6. Duncan R. L., Jr, Morrison D. C. The fate of E. coli lipopolysaccharide after the uptake of E. coli by murine macrophages in vitro. J Immunol. 1984 Mar;132(3):1416–1424. [PubMed] [Google Scholar]
  7. Dunn D. L., Ferguson R. M. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery. 1982 Aug;92(2):212–219. [PubMed] [Google Scholar]
  8. Emanuel D., Peppard J., Chehimi J., Hammerling U., O'Reilly R. The diagnostic, prophylactic, and therapeutic uses of monoclonal antibodies to human cytomegalovirus. Transplant Proc. 1987 Dec;19(6 Suppl 7):132–137. [PubMed] [Google Scholar]
  9. Flynn P. M., Shenep J. L., Gigliotti F., Davis D. S., Hildner W. K. Immunolabeling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli. Infect Immun. 1988 Oct;56(10):2760–2762. doi: 10.1128/iai.56.10.2760-2762.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gigliotti F., Shenep J. L. Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli. J Infect Dis. 1985 Jun;151(6):1005–1011. doi: 10.1093/infdis/151.6.1005. [DOI] [PubMed] [Google Scholar]
  11. Goldman R. C., Leive L. Heterogeneity of antigenic-side-chain length in lipopolysaccharide from Escherichia coli 0111 and Salmonella typhimurium LT2. Eur J Biochem. 1980;107(1):145–153. doi: 10.1111/j.1432-1033.1980.tb04635.x. [DOI] [PubMed] [Google Scholar]
  12. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  13. Greisman S. E., DuBuy J. B., Woodward C. L. Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice. Proc Soc Exp Biol Med. 1978 Jul;158(3):482–490. doi: 10.3181/00379727-158-40231. [DOI] [PubMed] [Google Scholar]
  14. Hitchcock P. J., Leive L., Mäkelä P. H., Rietschel E. T., Strittmatter W., Morrison D. C. Lipopolysaccharide nomenclature--past, present, and future. J Bacteriol. 1986 Jun;166(3):699–705. doi: 10.1128/jb.166.3.699-705.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kelly N. M., Young L., Cross A. S. Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes. Infect Immun. 1991 Dec;59(12):4491–4496. doi: 10.1128/iai.59.12.4491-4496.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Khazaeli M. B., Rogers K. J., LoBuglio A. F. Quantitative assay of a human monoclonal IgM antibody (HA-1A) in human serum. J Immunol Methods. 1989 Feb 24;117(2):175–180. doi: 10.1016/0022-1759(89)90138-5. [DOI] [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Lee C. J. The quantitative immunochemical determination of pneumococcal and meningococcal capsular polysaccharides by light scattering rate nephelometry. J Biol Stand. 1983 Jan;11(1):55–64. doi: 10.1016/s0092-1157(83)80046-8. [DOI] [PubMed] [Google Scholar]
  19. Mattsby-Baltzer I., Kaijser B. Lipid A and anti-lipid A. Infect Immun. 1979 Mar;23(3):758–763. doi: 10.1128/iai.23.3.758-763.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McCabe W. R. Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol. 1972 Mar;108(3):601–610. [PubMed] [Google Scholar]
  21. Munford R. S., Hall C. L., Rick P. D. Size heterogeneity of Salmonella typhimurium lipopolysaccharides in outer membranes and culture supernatant membrane fragments. J Bacteriol. 1980 Nov;144(2):630–640. doi: 10.1128/jb.144.2.630-640.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mutharia L. M., Crockford G., Bogard W. C., Jr, Hancock R. E. Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species. Infect Immun. 1984 Sep;45(3):631–636. doi: 10.1128/iai.45.3.631-636.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Overbeek B. P., Schellekens J. F., Lippe W., Dekker B. A., Verhoef J. Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5. J Clin Microbiol. 1987 Jun;25(6):1009–1013. doi: 10.1128/jcm.25.6.1009-1013.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Palva E. T., Mäkelä P. H. Lipopolysaccharide heterogeneity in Salmonella typhimurium analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Eur J Biochem. 1980;107(1):137–143. doi: 10.1111/j.1432-1033.1980.tb04634.x. [DOI] [PubMed] [Google Scholar]
  25. Pennington J. E., Menkes E. Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia. J Infect Dis. 1981 Dec;144(6):599–603. doi: 10.1093/infdis/144.6.599. [DOI] [PubMed] [Google Scholar]
  26. Peterson A. A., McGroarty E. J. High-molecular-weight components in lipopolysaccharides of Salmonella typhimurium, Salmonella minnesota, and Escherichia coli. J Bacteriol. 1985 May;162(2):738–745. doi: 10.1128/jb.162.2.738-745.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pollack M., Chia J. K., Koles N. L., Miller M., Guelde G. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis. 1989 Feb;159(2):168–188. doi: 10.1093/infdis/159.2.168. [DOI] [PubMed] [Google Scholar]
  28. Pollack M., Huang A. I., Prescott R. K., Young L. S., Hunter K. W., Cruess D. F., Tsai C. M. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983 Dec;72(6):1874–1881. doi: 10.1172/JCI111150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pollack M., Raubitschek A. A., Larrick J. W. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest. 1987 May;79(5):1421–1430. doi: 10.1172/JCI112970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Raetz C. R. Biochemistry of endotoxins. Annu Rev Biochem. 1990;59:129–170. doi: 10.1146/annurev.bi.59.070190.001021. [DOI] [PubMed] [Google Scholar]
  31. Rivera M., Bryan L. E., Hancock R. E., McGroarty E. J. Heterogeneity of lipopolysaccharides from Pseudomonas aeruginosa: analysis of lipopolysaccharide chain length. J Bacteriol. 1988 Feb;170(2):512–521. doi: 10.1128/jb.170.2.512-521.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rocque W. J., Coughlin R. T., McGroarty E. J. Lipopolysaccharide tightly bound to porin monomers and trimers from Escherichia coli K-12. J Bacteriol. 1987 Sep;169(9):4003–4010. doi: 10.1128/jb.169.9.4003-4010.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sakulramrung R., Domingue G. J. Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5. J Infect Dis. 1985 Jun;151(6):995–1004. doi: 10.1093/infdis/151.6.995. [DOI] [PubMed] [Google Scholar]
  34. Shenep J. L., Mogan K. A. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1984 Sep;150(3):380–388. doi: 10.1093/infdis/150.3.380. [DOI] [PubMed] [Google Scholar]
  35. Siegel S. A., Evans M. E., Pollack M., Leone A. O., Kinney C. S., Tam S. H., Daddona P. E. Antibiotics enhance binding by human lipid A-reactive monoclonal antibody HA-1A to smooth gram-negative bacteria. Infect Immun. 1993 Feb;61(2):512–519. doi: 10.1128/iai.61.2.512-519.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sternberg J. C. A rate nephelometer for measuring specific proteins by immunoprecipitin reactions. Clin Chem. 1977 Aug;23(8):1456–1464. [PubMed] [Google Scholar]
  37. Strittmatter W., Galanos C. Characterisation of protein co-extracted together with LPS in Escherichia coli, Salmonella minnesota and Yersinia enterocolitica. Microb Pathog. 1987 Jan;2(1):29–36. doi: 10.1016/0882-4010(87)90112-4. [DOI] [PubMed] [Google Scholar]
  38. Teng N. N., Kaplan H. S., Hebert J. M., Moore C., Douglas H., Wunderlich A., Braude A. I. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1790–1794. doi: 10.1073/pnas.82.6.1790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tesh V. L., Duncan R. L., Jr, Morrison D. C. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing. J Immunol. 1986 Aug 15;137(4):1329–1335. [PubMed] [Google Scholar]
  40. Tesh V. L., Morrison D. C. The physical-chemical characterization and biologic activity of serum released lipopolysaccharides. J Immunol. 1988 Nov 15;141(10):3523–3531. [PubMed] [Google Scholar]
  41. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Tsai C. M., Boykins R., Frasch C. E. Heterogeneity and variation among Neisseria meningitidis lipopolysaccharides. J Bacteriol. 1983 Aug;155(2):498–504. doi: 10.1128/jb.155.2.498-504.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tsai C. M., Frasch C. E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982 Jan 1;119(1):115–119. doi: 10.1016/0003-2697(82)90673-x. [DOI] [PubMed] [Google Scholar]
  44. Vukajlovich S. W. Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A. Infect Immun. 1986 Sep;53(3):480–485. doi: 10.1128/iai.53.3.480-485.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Weiss J., Hutzler M., Kao L. Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein. Infect Immun. 1986 Feb;51(2):594–599. doi: 10.1128/iai.51.2.594-599.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ziegler E. J., Douglas H., Sherman J. E., Davis C. E., Braude A. I. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol. 1973 Aug;111(2):433–438. [PubMed] [Google Scholar]
  47. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  48. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES